Market Overview

UPDATE: Benchmark Downgrades BioClinica to Hold Following Sale Agreement

Related BIOC
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois
Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy
Biocept files for secondary equity offering; shares down 9% (Seeking Alpha)

Benchmark downgraded BioClinica, Inc (NASDAQ: BIOC) from Buy to Hold and maintained a $7.25 price target.

Benchmark said, "BioClinica announced it has entered into a definitive agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. This reflects 1.6x our forecast 2012 revenue of $77.4 million and is a 23% premium to the prior 90-day trading average. … Based on the current price of $7.21, we feel shares now reflect our anticipation this transaction will shortly be completed. Our downgrade to Hold reflects the limited upside to the agreed $7.25 transaction price."

BioClinica closed at $7.21 on Wednesday.

Latest Ratings for BIOC

Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy
Aug 2015H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Downgrades Analyst Ratings


Related Articles (BIOC)

View Comments and Join the Discussion!

Partner Center